

Nina Bhardwaj

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8074313/nina-bhardwaj-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

268
papers

24,119
citations

74
h-index

153
g-index

292
ext. papers

28,009
ext. citations

11.1
avg, IF

6.88
L-index

#	Paper	IF	Citations
268	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	7
267	Spatial CRISPR genomics identifies regulators of the tumor microenvironment.. <i>Cell</i> , 2022 ,	56.2	7
266	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.. <i>EClinicalMedicine</i> , 2022 , 45, 101323	11.3	4
265	621 NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients 2021 , 9, A651-A651		
264	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	3
263	314 NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer 2021 , 9, A338-A338		
262	772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination 2021 , 9, A807-A807		
261	Martin A. "Mac" Cheever, MD: In Memoriam (1944-2021). <i>Cancer Immunology Research</i> , 2021 , 9, 1244	12.5	
260	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. <i>Cancer Cell</i> , 2021 , 39, 1442-1444	24.3	25
259	Uncloaking Breast Tumor Neoantigens with Radiation. <i>Trends in Immunology</i> , 2021 , 42, 277-279	14.4	1
258	Therapeutic cancer vaccines. <i>Nature Reviews Cancer</i> , 2021 , 21, 360-378	31.3	125
257	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. <i>Clinical Cancer Research</i> , 2021 , 27, 4287-4300	12.9	9
256	Vaccines for immunoprevention of cancer. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	3
255	MMP2 and TLRs modulate immune responses in the tumor microenvironment. <i>JCI Insight</i> , 2021 , 6,	9.9	4
254	Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. <i>Cell</i> , 2021 , 184, 3962-3980.e17	56.2	26
253	CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model. <i>Oncogene</i> , 2021 , 40, 396-407	9.2	9
252	Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 121-129	2.8	10

251	Intravenous nanoparticle vaccination generates stem-like TCF1 neoantigen-specific CD8 T cells. <i>Nature Immunology</i> , 2021 , 22, 41-52	19.1	29
250	Super(antigen) target for SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2021 , 21, 72	36.5	5
249	PD-1 inhibition in advanced myeloproliferative neoplasms. <i>Blood Advances</i> , 2021 , 5, 5086-5097	7.8	1
248	Tumor organoid-originated biomarkers predict immune response to PD-1 blockade. <i>Cancer Cell</i> , 2021 , 39, 1187-1189	24.3	0
247	Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. <i>Frontiers in Immunology</i> , 2021 , 12, 757804	8.4	3
246	A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. <i>STAR Protocols</i> , 2021 , 2, 100758	1.4	0
245	Current Melanoma Treatments: Where Do We Stand?. <i>Cancers</i> , 2021 , 13,	6.6	25
244	Cross-Presentation of Tumor Antigens Is Ruled by Synaptic Transfer of Vesicles among Dendritic Cell Subsets. <i>Cancer Cell</i> , 2020 , 37, 751-753	24.3	6
243	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020 , 52, 910-941	32.3	962
242	A conserved dendritic-cell regulatory program limits antitumour immunity. <i>Nature</i> , 2020 , 580, 257-262	50.4	179
241	A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. <i>Genome Medicine</i> , 2020 , 12, 24	14.4	12
240	Computational Prediction and Validation of Tumor-Associated Neoantigens. <i>Frontiers in Immunology</i> , 2020 , 11, 27	8.4	35
239	EPCO-22. IDENTIFYING NEOANTIGENS FOR A PERSONALIZED MUTATION-DERIVED GENOMIC VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020 , 22, ii73-ii74	1	
238	CTIM-17. PHASE I STUDY OF THE SAFETY AND IMMUNOGENICITY OF PERSONALIZED NEOANTIGEN VACCINES AND TUMOR TREATING FIELDS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020 , 22, ii36-ii36	1	0
237	Landscape of natural killer cell activity in head and neck squamous cell carcinoma 2020 , 8,		14
236	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 450-464	12.9	28
235	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2020 , 8, 70-80	12.5	19
234	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020 , 183, 347-362.e24	56.2	128

233	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. <i>Cell</i> , 2020 , 183, 818-834.e13	56.2	105
232	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 ,	2.8	2
231	Unexplored horizons of cDC1 in immunity and tolerance. <i>Advances in Immunology</i> , 2020 , 148, 49-91	5.6	4
230	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.. <i>Nature Cancer</i> , 2020 , 1, 1204-1217	15.4	21
229	Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. <i>Cell</i> , 2020 , 183, 1634-1649.e17	56.2	36
228	Harnessing Natural Killer Cell Function for Genitourinary Cancers. <i>Urologic Clinics of North America</i> , 2020 , 47, 433-442	2.9	2
227	Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial. <i>Frontiers in Immunology</i> , 2019 , 10, 725	8.4	32
226	Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. <i>Cancer Discovery</i> , 2019 , 9, 1192-1207	24.4	41
225	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019 , 76, 599-603	10.2	50
224	Dendritic cell subsets and locations. <i>International Review of Cell and Molecular Biology</i> , 2019 , 348, 1-68	6	62
223	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9538-9538	2.2	3
222	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14307-e14307	2.2	2
221	P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1 β in a Human Tonsil Explant Model. <i>Journal of Virology</i> , 2019 , 93,	6.6	18
220	Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. <i>Cell Reports</i> , 2018 , 23, 512-521	10.6	43
219	Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. <i>Trends in Cancer</i> , 2018 , 4, 119-137	12.5	144
218	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018 , 73, 751-759	10.2	67
217	Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 4937-4948	12.9	61
216	Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis 2018 , 6, 38		6

215 Dendritic Cell Biology **2018**, 247-260.e6

214 Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity. *Cell Reports*, **2018**, 24, 1902-1915.e6 10.6 68

213 Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. *World Journal of Urology*, **2018**, 36, 1741-1748 4 8

212 Towards superior dendritic-cell vaccines for cancer therapy. *Nature Biomedical Engineering*, **2018**, 2, 341-346 14.6 55

211 Modulation of human Th17 cell responses through complement receptor 3 (CD11 b/CD18) ligation on monocyte-derived dendritic cells. *Journal of Autoimmunity*, **2018**, 92, 57-66 15.5 13

210 A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer.. *Journal of Clinical Oncology*, **2018**, 36, TPS3116-TPS3116 2.2 2

209 ATIM-31. PHASE I STUDY OF TUMOR TREATMENT FIELDS AND A PERSONALIZED MUTATION-DERIVED TUMOR VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi8-vi8 1 78

208 A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab **2018**, 6, 90 17

207 EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. *Nature Communications*, **2018**, 9, 3503 17.4 124

206 A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. *Nature Medicine*, **2018**, 24, 1178-1191 50.5 404

205 Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. *Cancer Journal (Sudbury, Mass)*, **2017**, 23, 131-137 2.2 7

204 Dendritic cell-based immunotherapy. *Cell Research*, **2017**, 27, 74-95 24.7 328

203 Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab **2017**, 5, 67 19

202 Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial. *Frontiers in Immunology*, **2017**, 8, 1808.4 30

201 Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. *Current Opinion in Immunology*, **2017**, 47, 35-43 7.8 32

200 Sequence-Specific Sensing of Nucleic Acids. *Trends in Immunology*, **2017**, 38, 53-65 14.4 30

199 Dendritic Cells **2017**, 126-144.e6 4

198 Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. *JCI Insight*, **2017**, 2, 9.9 30

197	Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3106-TPS3106	2.2	3
196	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3114-TPS3114	2.2	4
195	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 300-300	2.2	5
194	Correlation of consistent blood-based gene expression with change in CTLA4 in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6-6	2.2	
193	Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 166-166	2.2	
192	Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. <i>Cancer Cell</i> , 2016 , 30, 324-336	24.3	426
191	The Human Vaccines Project: A roadmap for cancer vaccine development. <i>Science Translational Medicine</i> , 2016 , 8, 334ps9	17.5	115
190	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials 2016 , 4, 15		47
189	Modulation of innate immunity in the tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 1261-8	7.4	49
188	In situ vaccination for the treatment of cancer. <i>Immunotherapy</i> , 2016 , 8, 315-30	3.8	51
187	Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells. <i>Journal of Leukocyte Biology</i> , 2016 , 99, 723-34	6.5	34
186	Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies. <i>Blood</i> , 2016 , 128, 818-818	2.2	4
185	Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3084-3084	2.2	1
184	In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3086-3086	2.2	2
183	A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9589-9589	2.2	11
182	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 357-357	2.2	20
181	Natural pattern-recognition-receptor agonists in prophylactic vaccines for in situ vaccination of lymphoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14516-e14516	2.2	
180	CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells. <i>PLoS Pathogens</i> , 2016 , 12, e1005553	7.6	24

179	Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 246-53	3.1	58
178	Dendritic Cell Vaccines. <i>Methods in Molecular Biology</i> , 2016 , 1403, 763-77	1.4	9
177	Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. <i>Immunity</i> , 2016 , 44, 924-38	32.3	544
176	Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. <i>Cancer Immunology Research</i> , 2015 , 3, 278-287	12.5	63
175	Requirement for innate immunity and CD90+ NK1.1 ⁺ lymphocytes to treat established melanoma with chemo-immunotherapy. <i>Cancer Immunology Research</i> , 2015 , 3, 296-304	12.5	18
174	Cancer immunotherapy: dendritic-cell vaccines on the move. <i>Nature</i> , 2015 , 519, 300-1	50.4	61
173	Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. <i>Vaccine</i> , 2015 , 33, 388-95	4.1	3
172	Attenuated <i>Listeria monocytogenes</i> vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 127-36	1.6	9
171	Dendritic cells and lymphoma cells: come together right now. <i>Blood</i> , 2015 , 125, 5-7	2.2	1
170	?????????????. <i>Nature Digest</i> , 2015 , 12, 30-32	0	
169	Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection. <i>Aids</i> , 2015 , 29, 1287-96	3.5	16
168	Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 15154-9	11.5	45
167	Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4586-4586	2.2	4
166	The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9065-9065	2.2	5
165	Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20057-e20057	2.2	0
164	Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14034-e14034	2.2	
163	In situ vaccine for low-grade lymphoma: Combination of intratumoral Flt3L and poly-ICLC with low-Dose radiotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3105-TPS3105	2.2	
162	Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 1851-1851	2.2	

161	Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy. <i>Oncology</i> , 2015 , 29, 970-2, 974-5	1.8	6
160	Dendritic cells in progression and pathology of HIV infection. <i>Trends in Immunology</i> , 2014 , 35, 114-22	14.4	54
159	Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. <i>Cancer Immunology Research</i> , 2014 , 2, 410-22	12.5	236
158	Activation and measurement of NLRP3 inflammasome activity using IL-1 β in human monocyte-derived dendritic cells. <i>Journal of Visualized Experiments</i> , 2014 ,	1.6	5
157	Activation of Toll-like receptor-2 by tumor associated matrix metalloproteinase-2 modulates dendritic cell function 2014 , 2,		78
156	Melanoma progression is associated with NK cell exhaustion 2014 , 2, O6		78
155	Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] 2014 , 2, P45		7
154	Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs. <i>Oncolmmunology</i> , 2014 , 3, e27580	7.2	2
153	Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. <i>Journal of Translational Medicine</i> , 2014 , 12, 342	8.5	16
152	Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 2202-2211	4.3	42
151	Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. <i>Cancer Immunology Research</i> , 2014 , 2, 720-4	12.5	86
150	Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. <i>Cell Reports</i> , 2014 , 9, 1856-1870	10.6	28
149	Reversal of natural killer cell exhaustion by TIM-3 blockade. <i>Oncolmmunology</i> , 2014 , 3, e946365	7.2	62
148	Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3204-5	2.2	7
147	HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 195-203	1.6	38
146	Turning a Tumor into a Vaccine Factory: In Situ Vaccination for Low-Grade Lymphoma. <i>Blood</i> , 2014 , 124, 5473-5473	2.2	3
145	Treatment of solid tumors with intratumoral poly-ICLC: A phase II clinical study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14010-e14010	2.2	1
144	Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20025-e20025	2.2	2

143	Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9119-TPS9119	2.2	1
142	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9086-9086	2.2	
141	Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3030-3030	2.2	
140	Association of natural killer (NK) cell exhaustion with melanoma progression.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9099-9099	2.2	
139	Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 811-22	7.4	85
138	Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells. <i>Experimental and Molecular Pathology</i> , 2013 , 95, 121-123	4.4	8
137	Plasmacytoid dendritic cells in HIV infection. <i>Advances in Experimental Medicine and Biology</i> , 2013 , 762, 71-107	3.6	50
136	Dendritic cell dysregulation during HIV-1 infection. <i>Immunological Reviews</i> , 2013 , 254, 170-89	11.3	63
135	Dendritic cell immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2013 , 1284, 31-45	6.5	40
134	A bloody mess: dendritic cells use hemophagocytosis to regulate viral inflammation. <i>Immunity</i> , 2013 , 39, 429-31	32.3	1
133	Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 280-8	3.1	113
132	Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. <i>Frontiers in Immunology</i> , 2013 , 4, 346	8.4	31
131	Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients. <i>European Journal of Immunology</i> , 2013 , 43, 1545-54	6.1	1
130	Phenotypic properties of transmitted founder HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 6626-33	11.5	293
129	Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. <i>Journal of Visualized Experiments</i> , 2013 ,	1.6	11
128	Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. <i>Frontiers in Immunology</i> , 2013 , 4, 436	8.4	14
127	Dendritic Cells 2013 , 117-133.e6		
126	Activation of the noncanonical NF- κ B pathway by HIV controls a dendritic cell immunoregulatory phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 14122-7	11.5	52

125	Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. <i>Modern Pathology</i> , 2012 , 25, 1000-10	9.8	49
124	Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2. <i>Onc Immunology</i> , 2012 , 1, 109-111	7.2	5
123	Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 6748-57	12.9	146
122	Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 535-44	3.1	25
121	Plasmacytoid dendritic cells lead the charge against tumors. <i>Journal of Clinical Investigation</i> , 2012 , 122, 481-4	15.9	2
120	HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4685-97	15.9	38
119	DCs and NK cells: critical effectors in the immune response to HIV-1. <i>Nature Reviews Immunology</i> , 2011 , 11, 176-86	36.5	152
118	Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. <i>Cancer Cell</i> , 2011 , 19, 333-46	24.3	46
117	miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. <i>Cancer Cell</i> , 2011 , 20, 104-18	24.3	278
116	CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1137-46	7.4	74
115	TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. <i>Cancer Research</i> , 2011 , 71, 5467-76	10.1	47
114	Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells. <i>Journal of Virology</i> , 2011 , 85, 6263-74	6.6	90
113	Oligonucleotide motifs that disappear during the evolution of influenza virus in humans increase alpha interferon secretion by plasmacytoid dendritic cells. <i>Journal of Virology</i> , 2011 , 85, 3893-904	6.6	50
112	MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. <i>Clinical Cancer Research</i> , 2011 , 17, 4309-19	12.9	72
111	Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN- β -producing and partially matured phenotype. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1088-101	15.9	102
110	Directing dendritic cell immunotherapy towards successful cancer treatment. <i>Immunotherapy</i> , 2010 , 2, 37-56	3.8	80
109	Toll-like receptor agonists: are they good adjuvants?. <i>Cancer Journal (Sudbury, Mass)</i> , 2010 , 16, 382-91	2.2	115
108	Evidence of dysregulation of dendritic cells in primary HIV infection. <i>Blood</i> , 2010 , 116, 3839-52	2.2	137

107	HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells. <i>European Journal of Immunology</i> , 2010 , 40, 2248-58	6.1	33
106	LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. <i>Journal of Clinical Investigation</i> , 2010 , 120, 4415-24	15.9	135
105	CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. <i>PLoS ONE</i> , 2010 , 5, e11144	3.7	84
104	Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. <i>Cancer Immunity</i> , 2010 , 10, 4		29
103	In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. <i>PLoS ONE</i> , 2009 , 4, e4256	3.7	32
102	HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine. <i>Clinical Cancer Research</i> , 2009 , 15, 299-306	12.9	17
101	Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. <i>Clinical Cancer Research</i> , 2009 , 15, 4467-74	12.9	18
100	Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 20429-34	11.5	257
99	Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation. <i>Journal of Immunology</i> , 2009 , 182, 6187-94	5.3	31
98	Phosphorylated 4E-BP1 is associated with poor survival in melanoma. <i>Clinical Cancer Research</i> , 2009 , 15, 2872-8	12.9	61
97	Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 1814-9	11.5	461
96	Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. <i>Virology</i> , 2009 , 383, 173-7	3.6	25
95	A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. <i>Vaccine</i> , 2009 , 27, 6088-94	4.1	64
94	Dendritic cells as targets for therapy in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 566-71	7.1	82
93	Dendritic cell function in HIV infection. <i>HIV Therapy</i> , 2009 , 3, 527-537		
92	Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors. <i>Journal of Immunotherapy</i> , 2009 , 32, 161-8	5	19
91	Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. <i>American Journal of Translational Research (discontinued)</i> , 2009 , 1, 35-43	3	32
90	Resolution of immune activation defines nonpathogenic SIV infection. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3512-5	15.9	33

89	Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. <i>Journal of Immunology</i> , 2008 , 181, 776-84	5.3	207
88	Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. <i>Cancer Research</i> , 2008 , 68, 9441-50	10.1	47
87	Innate immune responses in primary HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2008 , 3, 36-44	4.2	21
86	Quantitative effect of suboptimal codon usage on translational efficiency of mRNA encoding HIV-1 gag in intact T cells. <i>PLoS ONE</i> , 2008 , 3, e2356	3.7	44
85	KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3990-4001	15.9	25
84	HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3431-9	15.9	181
83	Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. <i>Journal of Translational Medicine</i> , 2007 , 5, 2	8.5	25
82	Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1. <i>European Journal of Immunology</i> , 2007 , 37, 1752-63	6.1	33
81	Exploiting dendritic cells for active immunotherapy of cancer and chronic infections. <i>Molecular Biotechnology</i> , 2007 , 36, 131-41	3	18
80	Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 8947-52	11.5	255
79	Biology of plasmacytoid dendritic cells and natural killer cells in HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2007 , 2, 189-200	4.2	4
78	Harnessing the immune system to treat cancer. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1130-6	15.9	88
77	Dendritic Cell Vaccines 2007 , 251-274		
76	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. <i>Cancer Immunity</i> , 2007 , 7, 11		65
75	Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. <i>Blood</i> , 2006 , 107, 1963-9	2.2	51
74	The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. <i>Blood</i> , 2006 , 108, 947-55	2.2	99
73	Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease.. <i>Blood</i> , 2006 , 108, 3397-3397	2.2	1
72	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. <i>Blood</i> , 2006 , 108, 3492-3492.2		1

71	Differentiation of peripheral blood monocytes into dendritic cells. <i>Current Protocols in Immunology</i> , 2005 , Chapter 22, Unit 22F.4	4	23
70	Plasmacytoid dendritic cells: linking innate and adaptive immunity. <i>Journal of Virology</i> , 2005 , 79, 17-27	6.6	283
69	The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. <i>Blood</i> , 2005 , 106, 167-74	2.2	166
68	Combining radiotherapy and immunotherapy: a revived partnership. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 655-66	4	265
67	Dendritic cell chic. <i>Seminars in Immunopathology</i> , 2005 , 26, 215-219		1
66	Recent advances in dendritic cell biology. <i>Journal of Clinical Immunology</i> , 2005 , 25, 87-98	5.7	37
65	Recent advances in dendritic cell biology. <i>Journal of Clinical Immunology</i> , 2005 , 25, 177-88	5.7	61
64	Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. <i>Journal of Experimental Medicine</i> , 2005 , 201, 891-902	16.6	198
63	Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. <i>Journal of Clinical Investigation</i> , 2005 , 115, 3265-75	15.9	505
62	CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients.. <i>Blood</i> , 2005 , 106, 356-356	2.2	1
61	Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. <i>Methods in Molecular Medicine</i> , 2005 , 109, 1-18		7
60	Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. <i>Methods in Molecular Medicine</i> , 2005 , 109, 97-112		21
59	Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. <i>Journal of Virology</i> , 2004 , 78, 5223-32	6.6	281
58	CD8 epitope escape and reversion in acute HCV infection. <i>Journal of Experimental Medicine</i> , 2004 , 200, 1593-604	16.6	263
57	Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. <i>Journal of Virology</i> , 2004 , 78, 6151-61	6.6	57
56	Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3834-5; author reply 3835	2.2	18
55	DC-virus interplay: a double edged sword. <i>Seminars in Immunology</i> , 2004 , 16, 147-61	10.7	44
54	Danger signals: a time and space continuum. <i>Trends in Molecular Medicine</i> , 2004 , 10, 251-7	11.5	95

53	Manipulating dendritic cell biology for the active immunotherapy of cancer. <i>Blood</i> , 2004 , 104, 2235-46	2.2	278
52	Dead-cell-associated proteins are an important source of antigens for cross-presentation by dendritic cells. <i>Nature Reviews Immunology</i> , 2004 , 4, 656-656	36.5	
51	Killed but Metabolically Active Recombinant <i>Listeria monocytogenes</i> as an Antigen Delivery and Activation Platform for Human Dendritic Cell-Based Cancer Immunotherapy.. <i>Blood</i> , 2004 , 104, 3447-3447 ²	2.2	1
50	Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. <i>Current HIV Research</i> , 2003 , 1, 205-16	1.3	12
49	Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. <i>Blood</i> , 2003 , 102, 4448-55	2.2	104
48	Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. <i>European Journal of Immunology</i> , 2003 , 33, 588-96	6.1	73
47	Against the self: dendritic cells versus cancer. <i>Apmis</i> , 2003 , 111, 805-17	3.4	5
46	Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. <i>Blood</i> , 2003 , 101, 3520-6	2.2	277
45	Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. <i>Current Opinion in Immunology</i> , 2002 , 14, 471-7	7.8	48
44	Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. <i>Journal of Virology</i> , 2002 , 76, 7528-34	6.6	131
43	Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. <i>Aids</i> , 2002 , 16, 171-80	3.5	34
42	Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. <i>Aids</i> , 2002 , 16, 1319-29	3.5	89
41	A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. <i>Vaccine</i> , 2002 , 20 Suppl 4, A8-A22	4.1	152
40	Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. <i>European Journal of Immunology</i> , 2001 , 31, 3432-42	6.1	87
39	Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. <i>Journal of Immunological Methods</i> , 2001 , 258, 111-26	2.5	80
38	Tethering and tickling: a new role for the phosphatidylserine receptor. <i>Journal of Cell Biology</i> , 2001 , 155, 501-4	7.3	115
37	Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. <i>Journal of Virology</i> , 2001 , 75, 2142-53	6.6	70
36	Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. <i>Journal of Immunology</i> , 2001 , 167, 4844-52	5.3	207

35	Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. <i>Journal of Experimental Medicine</i> , 2001 , 193, 233-8	16.6	1162
34	Dendritic cells resurrect antigens from dead cells. <i>Trends in Immunology</i> , 2001 , 22, 141-8	14.4	157
33	Processing and presentation of antigens by dendritic cells: implications for vaccines. <i>Trends in Molecular Medicine</i> , 2001 , 7, 388-94	11.5	70
32	Interactions of viruses with dendritic cells 2001 , 505-522		2
31	Dendritic cell-dead cell interactions: implications and relevance for immunotherapy. <i>Journal of Immunotherapy</i> , 2001 , 24, 294-304	5	18
30	Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. <i>Journal of Immunology</i> , 2000 , 165, 1182-90	5.3	112
29	Active immunization of humans with dendritic cells. <i>Journal of Clinical Immunology</i> , 2000 , 20, 167-74	5.7	27
28	Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. <i>Journal of Experimental Medicine</i> , 2000 , 191, 423-34	16.6	1209
27	Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. <i>Journal of Clinical Investigation</i> , 2000 , 105, R9-R14	15.9	160
26	Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. <i>Immunology Letters</i> , 1999 , 66, 121-8 ^{4.1}		54
25	A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. <i>Aids</i> , 1999 , 13, 767-77	3.5	176
24	Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. <i>Journal of Clinical Investigation</i> , 1999 , 104, 173-80	15.9	359
23	Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. <i>Nature</i> , 1998 , 392, 86-9	50.4	1975
22	Tumor-specific killer cells in paraneoplastic cerebellar degeneration. <i>Nature Medicine</i> , 1998 , 4, 1321-4	50.5	393
21	Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. <i>Journal of Cutaneous Pathology</i> , 1998 , 25, 79-88	1.7	53
20	The distinctive features of influenza virus infection of dendritic cells. <i>Immunobiology</i> , 1998 , 198, 552-67	3.4	97
19	Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. <i>Journal of Experimental Medicine</i> , 1998 , 188, 1359-68	16.6	1066
18	Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. <i>Journal of Experimental Medicine</i> , 1998 , 188, 2163-73	16.6	546

17	Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. <i>Journal of Virology</i> , 1998 , 72, 9788-94	6.6	75
16	A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines in Mediating the Terminal Maturation of Human Dendritic Cells. <i>Blood</i> , 1997 , 90, 3640-3646	2.2	207
15	Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. <i>Journal of Immunological Methods</i> , 1996 , 196, 121-35	2.5	590
14	Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. <i>Journal of Experimental Medicine</i> , 1996 , 184, 2433-8	16.6	220
13	Stimulation of human anti-viral CD8+ cytolytic T lymphocytes by dendritic cells. <i>Advances in Experimental Medicine and Biology</i> , 1995 , 378, 375-9	3.6	14
12	Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. <i>Arthritis and Rheumatism</i> , 1992 , 35, 35-42		244
11	Dendritic cells in human blood and synovial exudates. <i>International Reviews of Immunology</i> , 1990 , 6, 103-116	1.6	7
10	Immune Regulation	33-44	
9	Crossprocessing and Crosspresentation	427-453	
8	Global Cancer Transcriptome Quantifies Repeat Element Polarization Between Immunotherapy Responsive and T cell Suppressive Classes		1
7	Computational pipeline for the PGV-001 neoantigen vaccine trial		3
6	P2X antagonists inhibit HIV-1 productive infection and inflammatory cytokines IL-10 and IL-1 β in a human tonsil explant model		2
5	Widespread immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors		7
4	New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy		6
3	Y-RNAs Lead an Endogenous Program of RIG-I Agonism Mobilized upon RNA Virus Infection and Targeted by HIV		5
2	Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients		3
1	Perturb-map enables CRISPR genomics with spatial resolution and identifies regulators of tumor immune composition		2